Phyla launches professional phage serum for acne treatments

Phyla has introduced Phyla PRO Precision Phage Serum, a professional-use acne product designed for in-office procedures and built with 8 times the phage concentration of the company’s consumer serum. The launch expands Phyla’s bacteriophage approach from home skincare into professional treatment protocols as research interest in C. acnes-targeting phages grows.

Why it matters: - Phyla PRO brings bacteriophage-based acne care into professional treatment rooms, where clinicians can use it during or after pore-opening procedures. - The serum is designed to target acne-associated Cutibacterium acnes while preserving the broader skin microbiome. - The product gives skincare professionals a higher-potency option than Phyla’s consumer Acne Phage Serum.

What happened: - Phyla announced the launch of Phyla PRO Precision Phage Serum, a professional-use, high-potency phage serum for in-office acne-prone skin protocols. - The company said the new formula contains 8 times the phage concentration of Phyla’s consumer Acne Phage Serum. - Phyla said the serum is intended for use during or immediately after pore-opening aesthetic procedures.

The details: - Phyla PRO delivers targeted bacteriophages to help reduce acne-associated C. acnes. - The formula was developed to support acne-prone skin care in professional settings. - Phyla said the serum is made without fragrance, parabens, phthalates, alcohol, benzoyl peroxide or drying agents. - Human Repeat Insult Patch Testing found no irritation or sensitization under HRIPT conditions. - Phyla PRO requires refrigerated storage at 2–8°C / 36–46°F when not in use to maintain phage efficacy. - The company cited peer-reviewed research on C. acnes-targeting bacteriophages, including a 2023 Nature Communications study that reported reduced bacterial load and inflammation in an in-vivo acne model. - Phyla also cited a 2026 Scientific Reports proof-of-concept study that found topical C. acnes phage therapy reduced inflammatory and non-inflammatory acne lesions in humans while selectively sparing other skin bacteria. - Phyla’s scientific references also include a 2026 Journal of Drugs in Dermatology study titled “Randomized Controlled Study of Bacteriophages in Acne Reveals Efficacy and Novel Mechanism for Promoting Long-Term Skin Health.” - The company described itself as a biotechnology-driven skincare company using patented phage technology to selectively target bacteria associated with skin conditions while preserving the broader skin microbiome.

Between the lines: - The launch signals that Phyla is trying to move phage skincare beyond consumer use and into clinician-led acne protocols. - The emphasis on microbiome preservation positions the product as an alternative to more drying acne treatments. - The refrigeration requirement suggests the product is more operationally specialized than standard skincare formulas.

What's next: - Phyla is likely to market the serum to dermatology and aesthetics practices that perform acne-focused procedures. - The company is positioning its broader phage platform around additional professional and microbiome-conscious skin applications. - More clinical and peer-reviewed data will likely shape how quickly the product is adopted in practice.

The bottom line: - Phyla is expanding its bacteriophage acne strategy from at-home skincare to a higher-potency professional product built for in-office use.